As of Jul 27
| -0.0799 / -3.39%|
The 2 analysts offering 12-month price forecasts for Rexahn Pharmaceuticals Inc have a median target of 19.75, with a high estimate of 20.00 and a low estimate of 19.50. The median estimate represents a +766.23% increase from the last price of 2.28.
The current consensus among 2 polled investment analysts is to Buy stock in Rexahn Pharmaceuticals Inc. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.